Bevacizumab + Chemoimmunotherapy + Atezolizumab for Small Cell Lung Cancer
(BELIEVE Trial)
Trial Summary
What is the purpose of this trial?
This clinical trial aims to assess whether the addition of bevacizumab to atezolizumab and chemotherapy can improve response to treatment and progression-free survival in patients with extensive-stage small cell lung cancer (ES-SCLC) with liver metastases. The main questions it aims to answer are: * In patients with ES-SCLC with liver metastases, can bevacizumab in combination with atezolizumab and chemotherapy prolong the length of time that the cancer does not progress? * Is bevacizumab safe and tolerable when combined with atezolizumab and chemotherapy in patients with ES-SCLC and liver metastases? The study treatment includes two phases: * Induction phase: bevacizumab will be administered in combination with atezolizumab and chemotherapy on a 21-day cycle for four cycles. * Maintenance: atezolizumab and bevacizumab will be administered every 21 days for up to 12 months, or until unacceptable toxicity or disease progression. Participants will undergo blood tests every 3 weeks and tumor assessments every 6 weeks.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, certain medications like high-dose aspirin, some anticoagulants, and systemic immunosuppressive medications are restricted. It's best to discuss your current medications with the trial team to see if any adjustments are needed.
What data supports the effectiveness of the drug combination Bevacizumab, Atezolizumab, and chemotherapy for small cell lung cancer?
Research shows that adding atezolizumab to chemotherapy improves survival in patients with extensive-stage small cell lung cancer. Additionally, combining atezolizumab and bevacizumab with chemotherapy has shown effectiveness in treating other types of lung cancer, suggesting potential benefits for small cell lung cancer as well.12345
Is the combination of Bevacizumab, Chemoimmunotherapy, and Atezolizumab generally safe for humans?
Bevacizumab, also known as Avastin, has been studied for safety in various cancers, including non-small cell lung cancer. Common side effects include bleeding, high blood pressure, and protein in the urine, but these are usually manageable with standard care. Serious side effects are rare, and the treatment is generally considered safe when monitored properly.678910
How is the drug Bevacizumab + Chemoimmunotherapy + Atezolizumab unique for treating small cell lung cancer?
Research Team
Kamya Sankar, MD
Principal Investigator
Cedars-Sinai Cancer
Eligibility Criteria
This trial is for adults with extensive-stage small cell lung cancer (ES-SCLC) that has spread to the liver. They should not have had prior treatment for ES-SCLC, be in a stable condition (ECOG 0-2), and able to follow study procedures. Women must use birth control, and men agree to use condoms. People with certain health conditions or who've had specific treatments recently are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Induction
Bevacizumab is administered in combination with atezolizumab and chemotherapy on a 21-day cycle for four cycles
Maintenance
Atezolizumab and bevacizumab are administered every 21 days for up to 12 months, or until unacceptable toxicity or disease progression
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Bevacizumab
Bevacizumab is already approved in European Union, United States, Japan, Canada for the following indications:
- Colorectal cancer
- Breast cancer
- Non-small cell lung cancer
- Renal cell carcinoma
- Ovarian cancer
- Colorectal cancer
- Non-small cell lung cancer
- Glioblastoma
- Renal cell carcinoma
- Cervical cancer
- Ovarian cancer
- Colorectal cancer
- Non-small cell lung cancer
- Breast cancer
- Renal cell carcinoma
- Ovarian cancer
- Colorectal cancer
- Non-small cell lung cancer
- Breast cancer
- Renal cell carcinoma
- Ovarian cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Kamya Sankar
Lead Sponsor
University of Michigan
Collaborator
Genentech, Inc.
Industry Sponsor
Ashley Magargee
Genentech, Inc.
Chief Executive Officer since 2024
MBA from Harvard University, BA from Princeton University
Levi Garraway
Genentech, Inc.
Chief Medical Officer since 2021
MD, PhD
VA Ann Arbor Healthcare System
Collaborator